Their work emphasizes targets in the inositol phosphate metabolism pathway and CHRM3, aiming to highlight drugs and compounds in development for COPD and asthma, as well as potential drug repositioning opportunities from other clinical fields. The gene discussed is CHRM3; the disease is asthma.